Array BioPharma appoints vp of clinical development
Bengt Berstrom has joined biopharmaceutical firm Array BioPharma as vp of clinical development.
With more than 17 years" working in the pharmaceutical industry, Dr Bergstrom will lead Array's clinical science and drug safety activities for its growing pipeline of targeted small molecule drugs to treat cancer and inflammatory diseases.
"Bengt's expertise in advancing cancer and inflammation therapeutics, including oral cancer therapies such as Xeloda, will be a competitive advantage for Array as we progress our five wholly owned drugs in human clinical development," said chief executive Robert Conway.
Prior to joining Array, Dr Bergstrom held various roles Hoffmann-La Roche, most recently as clinical science leader in oncology drug development.
Dr Bergstrom studied at the University of Lund in Sweden where he received his MD and PhD.
You may also like
Research & Development
Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications
Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether